Results and Prognostic Factors Following Optimal Treatment of Advanced Hodgkin’s Disease

The introduction of the MOPP (mustine, oncovin, procarbazine, and prednisone) combination by DeVita and colleagues (Longo et al. 1986) represented a dramatic advance in the treatment of patients with advanced Hodgkin’s disease. The complete remission (CR) rate at Memorial Hospital was at the lower end of those reported in the literature, perhaps reflecting the inclusion of advanced Hodgkin’s disease patients with a worse prognosis than those seen in other centers.